Ultralife Future Growth

Future criteria checks 1/6

Ultralife is forecast to grow earnings and revenue by 14.3% and 5.9% per annum respectively while EPS is expected to grow by 15.2% per annum.

Key information

14.3%

Earnings growth rate

15.2%

EPS growth rate

Electrical earnings growth	20.9%
Revenue growth rate	5.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	26 Jun 2024

Recent future growth updates

Recent updates

Ultralife Corporation Is Attractive Here

Jun 30

Ultralife Corporation: Ready To Surge

Apr 22

These 4 Measures Indicate That Ultralife (NASDAQ:ULBI) Is Using Debt Reasonably Well

Apr 16

Slowing Rates Of Return At Ultralife (NASDAQ:ULBI) Leave Little Room For Excitement

Mar 14

We Think Ultralife Corporation's (NASDAQ:ULBI) CEO Compensation Package Needs To Be Put Under A Microscope

Jul 15

Is Ultralife Corporation (NASDAQ:ULBI) Potentially Undervalued?

Apr 14

The Trends At Ultralife (NASDAQ:ULBI) That You Should Know About

Mar 09

Ultralife Corporation's (NASDAQ:ULBI) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 18

Ultralife reports Q4 results

Feb 04

If You Had Bought Ultralife (NASDAQ:ULBI) Stock Five Years Ago, You Could Pocket A 17% Gain Today

Feb 03

What Type Of Shareholders Make Up Ultralife Corporation's (NASDAQ:ULBI) Share Registry?

Jan 14

Are Insiders Buying Ultralife Corporation (NASDAQ:ULBI) Stock?

Dec 30

Is Ultralife (NASDAQ:ULBI) Using Too Much Debt?

Dec 15

Has Ultralife (NASDAQ:ULBI) Got What It Takes To Become A Multi-Bagger?

Dec 02

A Look At Ultralife's (NASDAQ:ULBI) CEO Remuneration

Nov 19

Earnings and Revenue Growth Forecasts

NasdaqGM:ULBI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	187	13	N/A	N/A	1
12/31/2024	172	11	N/A	N/A	1
3/31/2024	169	10	1	3	N/A
12/31/2023	159	7	-1	2	N/A
9/30/2023	150	4	0	2	N/A
6/30/2023	144	3	0	3	N/A
3/31/2023	133	0	-1	1	N/A
12/31/2022	132	0	-3	-1	N/A
9/30/2022	119	-1	-10	-8	N/A
6/30/2022	108	-1	-8	-6	N/A
3/31/2022	103	-1	-5	-3	N/A
12/31/2021	98	0	2	4	N/A
9/30/2021	103	3	5	9	N/A
6/30/2021	106	4	17	20	N/A
3/31/2021	108	5	23	26	N/A
12/31/2020	108	5	19	22	N/A
9/30/2020	110	5	20	23	N/A
6/30/2020	113	5	6	10	N/A
3/31/2020	114	6	-7	-3	N/A
12/31/2019	107	5	-9	-3	N/A
9/29/2019	97	23	-9	-1	N/A
6/30/2019	90	24	-2	5	N/A
3/31/2019	83	23	5	11	N/A
12/31/2018	87	25	7	11	N/A
9/30/2018	89	9	9	11	N/A
7/1/2018	89	9	4	5	N/A
4/1/2018	87	8	3	4	N/A
12/31/2017	86	8	N/A	7	N/A
10/1/2017	85	6	N/A	8	N/A
7/2/2017	83	6	N/A	12	N/A
4/2/2017	84	5	N/A	13	N/A
12/31/2016	82	4	N/A	8	N/A
9/25/2016	80	2	N/A	5	N/A
6/26/2016	79	2	N/A	3	N/A
3/27/2016	78	3	N/A	3	N/A
12/31/2015	76	3	N/A	9	N/A
9/27/2015	77	3	N/A	11	N/A
6/28/2015	74	2	N/A	7	N/A
3/29/2015	70	0	N/A	4	N/A
12/31/2014	66	-2	N/A	4	N/A
9/28/2014	67	-3	N/A	6	N/A
6/29/2014	71	-2	N/A	6	N/A
3/30/2014	73	-2	N/A	10	N/A
12/31/2013	79	-1	N/A	7	N/A
9/29/2013	88	1	N/A	6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ULBI's forecast earnings growth (14.3% per year) is above the savings rate (2.4%).

Earnings vs Market: ULBI's earnings (14.3% per year) are forecast to grow slower than the US market (14.7% per year).

High Growth Earnings: ULBI's earnings are forecast to grow, but not significantly.

Revenue vs Market: ULBI's revenue (5.9% per year) is forecast to grow slower than the US market (8.6% per year).

High Growth Revenue: ULBI's revenue (5.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ULBI's Return on Equity is forecast to be high in 3 years time

Ultralife Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target decreased by 7.7% to US$12.00

Consensus revenue estimates increase by 12%

Price target increased to US$12.00

Consensus revenue estimates fall by 14%

Recent updates

Ultralife Corporation Is Attractive Here

Ultralife Corporation, Annual General Meeting, Jul 16, 2024

Investor sentiment improves as stock rises 17%

Price target decreased by 7.7% to US$12.00

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation: Ready To Surge

These 4 Measures Indicate That Ultralife (NASDAQ:ULBI) Is Using Debt Reasonably Well

Ultralife Corporation to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Slowing Rates Of Return At Ultralife (NASDAQ:ULBI) Leave Little Room For Excitement

Full year 2023 earnings released: EPS: US$0.44 (vs US$0.007 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Insufficient Growth At Ultralife Corporation (NASDAQ:ULBI) Hampers Share Price

New major risk - Revenue and earnings growth

Ultralife Corporation to Report Q4, 2023 Results on Feb 15, 2024

Independent Chairman recently bought US$111k worth of stock

Independent Chairman recently bought US$181k worth of stock

Independent Chairman recently bought US$99k worth of stock

Investor sentiment deteriorates as stock falls 19%

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Is Now An Opportune Moment To Examine Ultralife Corporation (NASDAQ:ULBI)?

Ultralife Corporation to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 18%

Ultralife (NASDAQ:ULBI) May Have Issues Allocating Its Capital

Independent Chairman recently bought US$112k worth of stock

Investor sentiment improves as stock rises 27%

Consensus revenue estimates increase by 12%

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ultralife Corporation to Report Q2, 2023 Results on Jul 27, 2023

Independent Chairman recently bought US$398k worth of stock

Ultralife (NASDAQ:ULBI) Takes On Some Risk With Its Use Of Debt

Independent Chairman recently bought US$146k worth of stock

Ultralife Corporation, Annual General Meeting, Jul 19, 2023

Independent Chairman recently bought US$117k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$122k worth of stock

Full year 2022 earnings released: US$0.007 loss per share (vs US$0.015 loss in FY 2021)

Independent Chairman recently bought US$279k worth of stock

Ultralife Corporation Announces Executive Changes

Price target increased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Ultralife Corporation to Report Q3, 2022 Results on Oct 27, 2022

Ultralife (NASDAQ:ULBI) Is Carrying A Fair Bit Of Debt

Ultralife secures $7.5M communications systems contract

Independent Chairman recently bought US$158k worth of stock

Independent Chairman recently bought US$467k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ultralife receives $4.6M communications systems VAA order

Ultralife Corporation to Report Q2, 2022 Results on Jul 28, 2022

Independent Chairman recently bought US$219k worth of stock

Ultralife Corporation, Annual General Meeting, Jul 20, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Ultralife Corporation to Report Q1, 2022 Results on Apr 28, 2022

Does Ultralife (NASDAQ:ULBI) Have A Healthy Balance Sheet?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Chairman recently bought US$245k worth of stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 14%

Investor sentiment improved over the past week

Ultralife Corporation (NasdaqGM:ULBI) acquired Excell Battery Company for $23.5 million.

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.026 profit in 3Q 2020)

Independent Chairman recently bought US$199k worth of stock

Second quarter 2021 earnings released: EPS US$0.051 (vs US$0.10 in 2Q 2020)

We Think Ultralife Corporation's (NASDAQ:ULBI) CEO Compensation Package Needs To Be Put Under A Microscope

Ultralife Corporation(NasdaqGM:ULBI) dropped from Russell 2000 Defensive Index

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.042 (vs US$0.067 in 1Q 2020)

Is Ultralife Corporation (NASDAQ:ULBI) Potentially Undervalued?